Lantheus to Acquire Life Molecular Imaging for $350M Upfront with Potential $400M Earnout

Lantheus Holdings, Inc.

Upfront cash payment of $350M for Life Molecular Imaging, with up to $400M in potential earnout and milestone payments.
Acquisition adds Neuraceq (florbetaben F18), an FDA-approved PET imaging agent for Alzheimer's disease diagnosis.
Lantheus will assume up to $30M in seller's retained contingent liabilities under certain contractual arrangements.
Transaction expected to close in H2 2025, subject to Life Healthcare shareholder vote, antitrust clearances, and SA Reserve Bank approval.
Lantheus expects the deal to be accretive to adjusted EPS within 12 months of closing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.